Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.
Fiche publication
Date publication
avril 2023
Journal
Expert opinion on pharmacotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Goetsch A, D'Amico F, Allocca M, Fiorino G, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Janus kinase (JAK) inhibitors are an emerging class of small-molecule drugs, providing targeted therapy for a variety of diseases, and have made their way into the treatment of armamentarium of ulcerative colitis (UC) in recent years.
Mots clés
Filgotinib, JAK1, Upadacitinib, ivarmacitinib, ulcerative colitis
Référence
Expert Opin Pharmacother. 2023 04 11;:1-13